Anti-TNF-α inhibitors: A new therapeutic approach for inflammatory immune-mediated diseases: An update upon efficacy and adverse events

Giuseppe Murdaca, B. M. Colombo, F. Puppo

Research output: Contribution to journalArticle

Abstract

The ongoing progresses in the knowledge of the pathogenic mechanisms of various inflammatory or immune-mediated diseases and the availability of innovative biotechnological approaches have lead to the development of new drugs which add to conventional treatments. TNF-α inhibitors (Infliximab, Adalimumab and Etanercept) have demonstrated efficacy either as monotherapy or in combination with other anti-inflammatory or disease modifying anti-rheumatic drugs (DMARDs). The efficacy and safety profile of the TNF-α inhibitors can be considered, in general, as a class effect. Nevertheless, some differences may exist among the three agents. In this paper, we will briefly review the indications for the use of the three TNF-α inhibitors, the pre-treatment considerations and the reported adverse events.

Original languageEnglish
Pages (from-to)557-565
Number of pages9
JournalInternational Journal of Immunopathology and Pharmacology
Volume22
Issue number3
Publication statusPublished - Jul 2009

Keywords

  • Adverse events
  • TNF-α inhibitors
  • Tuberculosis

ASJC Scopus subject areas

  • Pharmacology
  • Immunology
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Anti-TNF-α inhibitors: A new therapeutic approach for inflammatory immune-mediated diseases: An update upon efficacy and adverse events'. Together they form a unique fingerprint.

  • Cite this